Kazia Therapeutics (KZIA) Financial Statements & Analysis

Kazia Therapeutics (KZIA) Income Statement

Kazia Therapeutics reported revenue of AUD 42.00K in fiscal 2025 (fiscal year ended Jun 30, 2025), down 98.2% from AUD 2.31M a year earlier. Kazia Therapeutics posted a net loss of AUD 20.70M, compared with a net loss of AUD 26.78M a year earlier. Gross margin was 99.4% and operating margin -33850.0%.

Kazia Therapeutics Income Statement Analysis

Values in millions AUD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Kazia Therapeutics Limited income statement - Annual data in millions AUD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020	Jun 2019	Jun 2018	Jun 2017
Revenue & Gross Profit
Revenue	0.04	2.31	0.00	0.01	15.18	0.99	0.00	0.01	8.79
Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.04	2.31	0.00	0.01	15.18	0.99	0.00	0.01	8.79
Operating Expenses
Research & Development	7.33	17.38	15.56	20.17	14.54	9.49	6.48	9.77	11.14
Selling, General & Administrative	8.72	13.56	8.58	5.24	7.02	3.69	3.79	5.60	8.53
Operating Expenses	14.26	30.77	24.15	25.41	21.56	13.18	10.25	14.69	19.66
Operating Income	-14.22	-28.46	-24.15	-25.40	-6.38	-12.20	-8.38	-12.49	-10.85
Other Income/Expense
Interest Income	0.07	0.01	0.02	0.00	0.04	0.07	0.10	0.12	0.00
Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	2.19	0.00	0.00
Other Income/Expense	-8.30	1.41	3.39	0.02	-2.53	-0.57	-1.75	6.02	0.01
Income
Income Before Tax	-22.45	-27.05	-20.74	-25.38	-8.90	-12.77	-10.57	-6.34	-10.87
Income Tax Expense	-1.75	-0.27	-0.27	-0.37	-0.48	-0.30	-0.30	-0.31	-0.20
Net Income	-20.70	-26.78	-20.47	-25.01	-8.42	-12.47	-10.27	-6.04	-10.67
Net Income - Continuous Operations	-20.70	-26.78	-20.47	-25.01	-8.42	-12.47	-10.27	-6.04	-10.67
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-	-
EBITDA	-13.28	-26.59	-22.28	-23.52	-5.11	-11.11	-7.71	-10.82	-9.44
EBIT	-14.22	-28.46	-24.15	-25.40	-6.38	-	-	-	-
Depreciation & Amortization	0.93	1.87	1.87	1.87	1.27	1.08	1.08	1.55	1.41
Earnings Per Share
Basic EPS	-19.00	-55.00	-56.00	-95.00	-36.00	-80.00	-86.00	-60.00	-109.00
Diluted EPS	-19.00	-55.00	-56.00	-95.00	-36.00	-80.00	-86.00	-60.00	-109.00
Basic Shares Outstanding	1.10	0.48	0.37	0.27	0.24	0.15	0.12	0.10	0.10
Diluted Shares Outstanding	1.10	0.48	0.37	0.27	0.24	0.15	0.12	0.10	0.10

Source: Company financial statements from annual and quarterly filings. Data as of Dec 31, 2025. Data sources and methodology

Frequently Asked Questions About Kazia Therapeutics Financial Statements

What was Kazia Therapeutics's revenue in fiscal 2025?

Kazia Therapeutics reported revenue of AUD 42.00K in fiscal 2025 (fiscal year ended Jun 30, 2025). That was down 98.2% from AUD 2.31M a year earlier.

Is Kazia Therapeutics profitable?

No. Kazia Therapeutics reported a net loss of AUD 20.70M in fiscal 2025. In fiscal 2024 it lost AUD 26.78M.

What is Kazia Therapeutics's operating margin?

Kazia Therapeutics's operating income was −AUD 14.22M on revenue of AUD 42.00K in fiscal 2025, an operating margin of -33850.0%, compared with -1233.2% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition